Clinicians Hesitant to Offer New Oral Immunotherapies Clinicians Hesitant to Offer New Oral Immunotherapies

Concerns over staffing needs and the risk for anaphylaxis with new oral immunotherapies have physicians questioning the next steps.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Allergy & Clinical Immunology News Source Type: news

Related Links:

Abstract Shrimp allergy, a common form of food allergy is an adverse immunological response to shrimp proteins. BALB/c mice was sensitized by an adjuvant free oral administration of purified tropomyosin, from Metpenaeus dobsonii to characterize intestinal histological responses and immunological protein recognition pattern as it is unpractical in human subjects. Sensitized mice with higher dose of tropomyosin expressed symptoms of anaphylaxis including puffiness around eyes and snout, no activity, tremor and convulsion after challenge. The responses of high level of sera IgE, tropomyosin specific IgE and histamine...
Source: Immunology Letters - Category: Allergy & Immunology Authors: Tags: Immunol Lett Source Type: research
Peanut allergy affects 1-2% of individuals in the United States, and is increasing in prevalence.1-4 Although there is accumulating data on immunotherapy for peanut allergy,5-8 the cornerstone of management remains strict avoidance of peanut protein, maintenance of an emergency action plan and prompt use of epinephrine to treat systemic reactions in case of an accidental exposure, which occurs in up to 12-15% of peanut-allergic individuals annually.9,10 Peanut allergy significantly impacts quality of life,11 as it is typically lifelong, is the leading cause of food-induced anaphylaxis in children, and the leading cause of ...
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: Source Type: research
Publication date: Available online 28 November 2019Source: The Journal of Allergy and Clinical Immunology: In PracticeAuthor(s): Paul J. Turner, Dianne E. Campbell, Megan S. Motosue, Ronna L. CampbellAbstractThe true global scale of anaphylaxis remains elusive, because many episodes occur in the community without presentation to healthcare facilities, and most regions have not yet developed reliable systems with which to monitor severe allergic events. The most robust datasets currently available are based largely on hospital admissions, which are limited by inherent issues of misdiagnosis, misclassification and generaliza...
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research
A recent study found that peanut OIT was associated with increased risk for anaphylaxis and serious adverse events, but the analysis leaves out some important considerations, says Dr Brian Vickery.Medscape Allergy &Immunology
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Allergy & Clinical Immunology Commentary Source Type: news
Abstract Stinging insect allergy is uncommon but can be life threatening. Diagnosis requires clinical history and confirmative skin or blood testing by an allergist. Baseline serum tryptase level can be used to stratify risk. Treatment is supportive for all reactions except for anaphylaxis, which is treated with intramuscular epinephrine, recumbent posture, and adjunct measures such as IV fluids, and oxygen. Venom immunotherapy is most effective for long-term management in patients with a history of anaphylaxis. Venom immunotherapy rapidly reduces the risk of sting anaphylaxis by up to 98% and maintenance treatmen...
Source: The Medical Clinics of North America - Category: General Medicine Authors: Tags: Med Clin North Am Source Type: research
Food allergy prevalence has increased over the past 2  decades and is estimated to affect 8% of children and 4% to 10% of adults. There is an unmet need to evaluate new therapeutic modalities that may decrease the risk of food-induced anaphylaxis and improve patients’ quality of life. Oral, epicutaneous, and sublingual food immunotherapies have diff erent safety and efficacy profiles, and their long-term outcome and applicability are unclear. Food allergy trials are currently evaluating different biologics (given as monotherapy or adjunct to immunotherapy), modified food proteins, DNA vaccines, and fecal microbiota transplantation.
Source: Immunology and Allergy Clinics of North America - Category: Allergy & Immunology Authors: Source Type: research
Subcutaneous immunotherapy (SCIT) is effective for allergic rhinitis and conjunctivitis, asthma, and insect venom hypersensitivity. The risk of severe allergic reactions induced by SCIT remains low, and mild systemic reactions have recently shown a tendency to decline. However, near-fatal and fatal anaphylactic reactions may occur. Clinicians administering allergen-specific immunotherapy should receive specialized training and be aware of risk factors and preventive measures to avoid severe allergic reactions induced by SCIT.
Source: Immunology and Allergy Clinics of North America - Category: Allergy & Immunology Authors: Source Type: research
This study sought to investigate these relationships and bridge the gap in the available medical literature on this topic.
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: Tags: Letters Source Type: research
Abstract Hymenoptera venom allergy is one of the common causes of anaphylaxis. However, when physicians make the diagnosis of Hymenoptera venom allergy, the histories of being stung are not always consistent with the results of venom specific IgE. With the development of component-resolved diagnosis, it is possible to accurately localize an allergic reaction to certain sensitized proteins. This paper reviewed the studies that have addressed the identified allergenicity and cross-reactivity of Hymenoptera venom allergens accepted by the WHO/IUIS Nomenclature Sub-committee, the component-resolved diagnosis of Hymeno...
Source: Current Protein and Peptide Science - Category: Biochemistry Authors: Tags: Curr Protein Pept Sci Source Type: research
Oral immunotherapy (OIT) for food allergy entails a risk of adverse reactions, including anaphylaxis. This safety concern is the major barrier for OIT to become a therapeutic option in clinical practice. The high heterogeneity in safety reporting of OIT studies prevents setting the safety profile accurately. An international consensus is needed to facilitate the analysis of large pooled clinical data with homogeneous safety reporting, that together with integrated omics, and patients/families ’ opinions, may help stratify the patients’ risk and needs, and help developing safe(r) individualized care pathways. Th...
Source: Immunology and Allergy Clinics of North America - Category: Allergy & Immunology Authors: Source Type: research
More News: Allergy | Allergy & Immunology | Anaphylactic Shock | Health | Immunotherapy